Browse
Submit Data
Databases
API
Help

Dataset Information

8 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Heat inactivation of the severe acute respiratory syndrome coronavirus 2.

ABSTRACT: Cell culture medium, nasopharyngeal and sera samples spiked with SARS-CoV-2 were subjected to heat inactivation for various periods of time, ranging from 30 s to 60 min. Our results showed that SARS-CoV-2 could be inactivated in less than 30 min, 15 min, and 3 min at 56 °C, 65 °C, and 95 °C, respectively. These data could help laboratory workers to improve their protocols by handling the virus in biosafety conditions.

SUBMITTER: Batejat C

PROVIDER: S-EPMC7825878 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates.

Project description:A novel human coronavirus causing severe acute respiratory syndrome (SARS) emerged in epidemic form in early 2003 in China and spread worldwide in a few months. Every newly emerging human pathogen is of concern for the safety of the blood supply during and after an epidemic crisis. For this purpose, we have evaluated the inactivation of SARS-coronavirus (CoV) in platelet concentrates using an approved pathogen inactivation device, the INTERCEPT Blood System. Apheresis platelet concentrates (APCs) were inoculated with approximately 10(6) pfu mL(-1) of either Urbani or HSR1 isolates of SARS-CoV. The inoculated units were mixed with 150 microm amotosalen and illuminated with 3 J cm(-2) UV-A light. The viral titres were determined by plaque formation in Vero E6 cells. Mixing SARS-CoV with APC in the absence of any treatment decreased viral infectivity by approximately 0.5-1 log10. Following photochemical treatment, SARS-CoV was consistently inactivated to the limit of detection in seven independent APC units. No infectious virus was detected after treatment when up to one-third of the APC unit was assayed, demonstrating a mean log10-reduction of >6.2. Potent inactivation of SARS-CoV therefore extends the capability of the INTERCEPT Blood System in inactivating a broad spectrum of human pathogens including recently emerging respiratory viruses.

| S-EPMC7169868 | biostudies-literature

Severe acute respiratory syndrome-associated coronavirus infection.

Project description:Whether severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection can be asymptomatic is unclear. We examined the seroprevalence of SARS-CoV among 674 healthcare workers from a hospital in which a SARS outbreak had occurred. A total of 353 (52%) experienced mild self-limiting illnesses, and 321 (48%) were asymptomatic throughout the course of these observations. None of these healthcare workers had antibody to SARS CoV, indicating that subclinical or mild infection attributable to SARS-CoV in adults is rare.

| S-EPMC3035556 | biostudies-literature

Severe acute respiratory syndrome coronavirus 2

Project description:SARS-Co-V-2 WGS: North Dakota Public Health Laboratory

| PRJNA691291 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Severe acute respiratory syndrome coronavirus 2

| PRJNA692476 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:SARS-CoV-2 Patient Sequencing from the Broad Institute

| PRJNA622837 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Targeted amplicon sequencing of wastewater samples for detecting SARS-CoV-2 variants with high sensitivity and resolution

| PRJDB15905 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:SELEX based aptamers: An excellent diagnostic and entry inhibitor therapeutic for SARS-CoV-2

| PRJDB15927 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Severe acute respiratory syndrome coronavirus 2 Genome sequencing

| PRJNA759255 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants

| PRJNA794206 | ENA

Severe acute respiratory syndrome coronavirus 2

Project description:EPICC SARS-CoV-2 Sequencing

| PRJNA723329 | ENA